Cargando…

Second- and third-generation ALK inhibitors for non-small cell lung cancer

Crizotinib as the first-generation ALK inhibitor has shown significant activity in ALK-mutated non-small cell lung cancer (NSCLC). Second- and third-generation ALK inhibitors are entering clinical applications for ALK+ NSCLC. In addition, a third-generation ALK inhibitor, lorlatinib (PF-06463922), w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Jingjing, Savooji, John, Liu, Delong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4782349/ https://www.ncbi.nlm.nih.gov/pubmed/26951079 http://dx.doi.org/10.1186/s13045-016-0251-8

Ejemplares similares

Alectinib and Brigatinib: New Second-Generation ALK Inhibitors for the Treatment of Non–Small Cell Lung Cancer
por: Beardslee, Tyler, et al.
Publicado: (2018)

Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer
por: Wang, Shuhang, et al.
Publicado: (2016)

Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non–Small Cell Lung Cancer Cells
por: Dong, Xuyuan, et al.
Publicado: (2016)

Sequential therapy with crizotinib and a second-generation ALK inhibitor versus direct therapy of a second-generation ALK inhibitor in ALK-positive advanced lung cancer: a real-world study
por: Wei, Jingwen, et al.
Publicado: (2023)

Second-generation inhibitors of Bruton tyrosine kinase
por: Wu, Jingjing, et al.
Publicado: (2016)

Outcomes of ALK positive lung cancer patients treated with crizotinib or second-generation ALK inhibitor: a monoinstitutional experience
por: De Carlo, Elisa, et al.
Publicado: (2018)

EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer
por: Wang, Shuhang, et al.
Publicado: (2016)

ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
por: Cang, Shundong, et al.
Publicado: (2015)

Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
por: Wu, Jingjing, et al.
Publicado: (2016)

Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer
por: Barrows, Stephanie M, et al.
Publicado: (2019)

Primary resistance to first- and second-generation ALK inhibitors in a non-small cell lung cancer patient with coexisting ALK rearrangement and an ALK F1174L-cis-S1189C de novo mutation: A case report
por: Zhao, Jiuzhou, et al.
Publicado: (2022)

Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib
por: van Erp, Anke E. M., et al.
Publicado: (2017)

A new ALK inhibitor overcomes resistance to first‐ and second‐generation inhibitors in NSCLC
por: Lu, Yue, et al.
Publicado: (2021)

Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors
por: Chia, Puey Ling, et al.
Publicado: (2014)

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK
por: Fontana, Diletta, et al.
Publicado: (2015)

The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer
por: Gristina, Valerio, et al.
Publicado: (2020)

EML4-ALK fusion gene in non-small cell lung cancer
por: Lei, Yu, et al.
Publicado: (2022)

Combined effect of ALK and MEK inhibitors in EML4–ALK-positive non-small-cell lung cancer cells
por: Tanizaki, J, et al.
Publicado: (2012)

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial
por: Camidge, D. Ross, et al.
Publicado: (2020)

The Cost-Effectiveness of Lorlatinib Versus Chemotherapy as a Second- or Third-Line Treatment in Anaplastic Lymphoma Kinase (ALK)-Positive Non-small-cell Lung Cancer in Sweden
por: Nilsson, Fredrik O. L., et al.
Publicado: (2021)

ALK inhibitors in ALK-rearranged non-small cell lung cancer with and without brain metastases: systematic review and network meta-analysis
por: Jiang, Jun, et al.
Publicado: (2022)

The efficacy and safety of ALK inhibitors in the treatment of ALK‐positive non‐small cell lung cancer: A network meta‐analysis
por: Fan, Junsheng, et al.
Publicado: (2018)

Retrospective Observational Study of ALK-Inhibitor Therapy Sequencing and Outcomes in Patients with ALK-Positive Non-small Cell Lung Cancer
por: Waterhouse, David M., et al.
Publicado: (2020)

Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors
por: Oulhen, Marianne, et al.
Publicado: (2021)

A Bayesian network meta‐analysis of ALK inhibitor treatments in patients with ALK‐positive non‐small cell lung cancer
por: Zheng, Bei, et al.
Publicado: (2023)

Comparison of efficacy and safety of second‐ and third‐generation TKIs for non‐small‐cell lung cancer with uncommon EGFR mutations
por: Hao, Yue, et al.
Publicado: (2023)

ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data
por: Moskovitz, Mor, et al.
Publicado: (2022)

Second generation tyrosine kinase inhibitors for the treatment of metastatic non-small-cell lung cancer
por: Stasi, Irene, et al.
Publicado: (2014)

Durable clinical response to ALK tyrosine kinase inhibitors in ALK-rearranged non-small cell lung cancer: a case report
por: Hu, Han, et al.
Publicado: (2022)

Fibroblast growth factor receptor 3 overexpression mediates ALK inhibitor resistance in ALK‐rearranged non–small cell lung cancer
por: Sakashita, Takuya, et al.
Publicado: (2022)

STK3-ALK, a Novel ALK Rearrangement in Non-Small Cell Lung Cancer With Sensitivity to Tyrosine Kinase Inhibitors: A Case Report
por: Feng, Chunlai, et al.
Publicado: (2021)

Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study
por: Duruisseaux, Michaël, et al.
Publicado: (2017)

ALK‐rearrangement in non‐small‐cell lung cancer (NSCLC)
por: Du, Xue, et al.
Publicado: (2018)

Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial
por: Christopoulos, Petros, et al.
Publicado: (2021)

Development of Furanopyrimidine-Based Orally Active Third-Generation EGFR Inhibitors for the Treatment of Non-Small Cell Lung Cancer
por: Li, Mu-Chun, et al.
Publicado: (2023)

Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with ALK Rearrangement
por: Oya, Yuko, et al.
Publicado: (2020)

ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis
por: Elliott, Jesse, et al.
Publicado: (2020)

Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative review
por: Desai, Aakash, et al.
Publicado: (2023)

Novel ALK inhibitors in clinical use and development
por: Iragavarapu, Chaitanya, et al.
Publicado: (2015)

Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4–ALK-rearranged non–small–cell lung cancer harbored coexisting EGFR mutation
por: Miyanaga, Akihiko, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_5she5ev11ns2s9iftc2v36uh6e